| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Steep Hill Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.006 |
| 52 Week High | CA$0.089 |
| 52 Week Low | CA$0.003 |
| Beta | 3.65 |
| 11 Month Change | -40.00% |
| 3 Month Change | -53.85% |
| 1 Year Change | -19.99% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| CD0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -29.4% | -1.8% | -1.8% |
| 1Y | -20.0% | -12.8% | 13.6% |
Return vs Industry: CD0 underperformed the German Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: CD0 underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| CD0 volatility | |
|---|---|
| CD0 Average Weekly Movement | 46.0% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CD0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CD0's weekly volatility has decreased from 133% to 46% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Sameet Kanade | www.steephill.com |
Steep Hill Inc. does not have significant operations. Previously, it operated as a cannabis-science company in Canada. The company was formerly known as Cannabis Clonal Corporation and changed its name to Steep Hill Inc. in February 2022.
Steep Hill Inc. Fundamentals Summary
| CD0 fundamental statistics | |
|---|---|
| Market cap | €213.39k |
| Earnings (TTM) | -€134.63k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.6x
P/E RatioIs CD0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CD0 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$204.14k |
| Earnings | -CA$204.14k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CD0 perform over the long term?
See historical performance and comparison